Latest Health News

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.

Raptis Group Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant share placement and entitlement offer, signaling a pivotal moment for the company’s capital structure.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Universal Biosensors reported a 6% increase in revenue for Q1 2025 but posted a net loss of A$3.84 million, with cash reserves sufficient only through Q3 2025, raising questions about its financial sustainability.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Envirosuite Limited has entered a binding Scheme Implementation Deed with UK-based Ideagen Limited, agreeing to a full acquisition at a significant premium. The transaction values Envirosuite at approximately A$132.2 million and awaits shareholder and regulatory approvals.

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Vitura Health reports sustained revenue and EBITDA growth in Q3 FY2025, driven by recent acquisitions and operational improvements, positioning the company well for FY2026.

Equinox Resources has successfully completed the first tranche of its $3.5 million capital raise, issuing nearly 31 million shares at 9.5 cents each. The second tranche, involving additional shares and options, is pending shareholder approval.

Macquarie Group Limited has announced a quarterly ordinary dividend of AUD 1.7124 per security on its perpetual capital notes, with a 35% franking rate and a total distribution yield of 6.79% per annum.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed a significant five-year, A$20 million contract to implement its cloud-based Visage 7 imaging platform at University of Iowa Health Care, marking a major step in cloud adoption for healthcare IT.

ARN Media Limited’s 2025 AGM update highlights robust financial health, a strategic $40 million transformation program, and strong digital audio momentum despite a modest revenue dip year-to-date.